| 摘要 |
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to derivatives of sulfonylamino acid and sulfonylaminohydroxaminic acid of the formula (I) , their pharmaceutically acceptable salts where W represents OH or NHOH; X means: a) heterocyclic radical taken among group including imidazolinyl, dihydrobenzoisothiazolyl and so on; b) -NR1SO2R2, where R1 means hydrogen atom; R2 means unsubstituted phenylalkyl and so on; Y means carbon or sulfur atom under condition that when Y means carbon atom then n = 2; Z means phenyl optionally substituted with halogen atom, unsubstituted alkoxy- group, phenyloxy-group optionally substituted with halogen atom, unsubstituted alkoxy-group, phenyloxy- group optionally substituted with halogen atom, phenyloxyimidazolyl, 4-methylpiperazinyl, 4-phenyl- piperidinyl, pyridinyloxy-group, where means hydrogen atom; means phenyl optionally substituted with hydroxy-group or phenyl, pyridinyl substituted with -CF3; m means a whole number from 1 to 4; n means a whole number 1 or 2. Invention relates also to method for preparing compound of the formula (I) by interaction of compound of the formula (IV) with compound of the formula (V) to yield compound of the formula (VI) that is converted to compound of the formula (I). Invention relates also to pharmaceutical composition inhibiting activity of metalloproteinase decomposing matrix that comprises effective amount of compound of the formula (I) and one or some pharmaceutically acceptable carriers. Invention provides the development of novel sulfonylamino-derivative inhibiting activity of metalloproteinase decomposing matrix. EFFECT: valuable biochemical properties of compounds. 9 cl, 2 tbl |
